Interleukin‐10 expressed at early tumour sites induces subsequent generation of CD4+ T‐regulatory cells and systemic collapse of antitumour immunity
- 1 August 2001
- journal article
- research article
- Published by Wiley in Immunology
- Vol. 103 (4) , 449-457
- https://doi.org/10.1046/j.1365-2567.2001.01279.x
Abstract
We investigated the relationship between transforming growth factor-β (TGF-β)-secreting T-regulatory (Tr) cells and anti-B16 melanoma immunity, and studied the association of early cytokines expressed at tumour sites with the generation of Tr cells. A large number of CD4+ Tr cells producing interleukin (IL)-4, IL-10 and TGF-β accumulated with functionally depressed CD8+ cytotoxic T lymphocytes (CTLs) at tumour sites on day 20 after subcutaneous (s.c.) inoculation of B16 tumour cells. Tr cells consisted of two populations, which were termed T helper 3 (Th3) and Tr1 cells. B16-infiltrating Tr cells strongly inhibited the generation of B16-specific T helper 1 (Th1) cells in a TGF-β-dependent manner and were assumed to suppress effective generation of CTLs. In addition, B16 cells markedly progressed in mice transferred adoptively by the cultured B16-infiltrating Tr cells compared with untreated mice. The capacity of these Tr cells to produce TGF-β was hampered by neutralizing anti-IL-10 and partly anti-IL-4 monoclonal antibodies (mAbs) injected intralesionally during the early development of B16 tumours, and this treatment markedly attenuated B16 growth. Furthermore, a lesional injection of recombinant mouse IL-10 at an early tumour site resulted in the vigorous progression of B16 tumours. These results provide evidence that Tr cells, belonging to the T helper 3/T-regulatory 1 (Th3/Tr1) type, are activated in B16-bearing hosts under the influence of T helper 2 (Th2) cytokines, mainly IL-10 (produced at early tumour lesions), and that this regulatory T-cell population functions as a suppressor of anti-B16 immunity.Keywords
This publication has 42 references indexed in Scilit:
- Downregulation of Innate and Acquired Antitumor Immunity by Bystander gamma delta and alpha beta T Lymphocytes with Th2 or Tr1 Cytokine ProfilesJournal of Interferon & Cytokine Research, 1999
- T Helper Cell Type 1–associated and Cytotoxic T Lymphocyte–mediated Tumor Immunity Is Impaired in Interleukin 4–deficient MiceThe Journal of Experimental Medicine, 1999
- REGULATION OF IMMUNE RESPONSES BY TGF-βAnnual Review of Immunology, 1998
- PRIMARY NONFUNCTION OF ISLET GRAFTS IN AUTOIMMUNE DIABETIC NONOBESE DIABETIC MICE IS PREVENTED BY TREATMENT WITH INTERLEUKIN-4 AND INTERLEUKIN-101Transplantation, 1996
- Suppression of cytotoxic T lymphocyte activity by ?/? T cells in tumor-bearing miceCancer Immunology, Immunotherapy, 1995
- Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo.The Journal of Experimental Medicine, 1994
- Immunotherapy with Low-dose Interleukin-2 and Antitransforming Growth Factor-β Antibody in a Murine Tumor ModelCancer Biotherapy, 1994
- Effects of Anti-transforming Growth Factor-β Antibody and Interleukin-2 in Tumor-bearing MiceCancer Biotherapy, 1993
- Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.The Journal of Experimental Medicine, 1992
- Effect of advanced aging on ability of mice to cause regression of an immunogenic lymphoma in response to immunotherapy based on depletion of suppressor T cellsCancer Immunology, Immunotherapy, 1991